![]() |
市场调查报告书
商品编码
1497782
癌症诊断中的人工智慧市场:按组成部分、部署、癌症类型和最终用户 - 2024-2030 年全球预测AI in Cancer Diagnostics Market by Component (Hardware, Services, Software), Deployment (Cloud, On-Premise), Cancer Type, End-user - Global Forecast 2024-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
癌症诊断领域的人工智慧市场规模预计2023年为2.2038亿美元,2024年达到2.6628亿美元,预计2030年将达到8.625亿美元,复合年增长率为21.52%。
癌症诊断中的人工智慧 (AI) 涉及使用先进的演算法和软体来处理、分析和解释医学影像和资料,以进行癌症检测、诊断和预测。这些由人工智慧主导的系统配备了机器学习和深度学习功能,使它们能够从大量肿瘤资料中学习,并随着时间的推移提高准确性和效率。全球人口中癌症盛行率的不断上升以及对个人化医疗的需求不断增长正在推动人工智慧在医疗保健领域的采用。此外,向非侵入性癌症诊断的快速转变,及其在世界各地多个癌症筛检计画中的快速采用,正在推动人工智慧在癌症治疗中的整合。然而,人工智慧整合癌症治疗的高成本以及缺乏训练有素的肿瘤学家正在影响人工智慧在癌症诊断市场的扩张。此外,政府投资支持的癌症诊断技术进步正在为市场成长创造有利可图的机会。
主要市场统计 | |
---|---|
基准年[2023] | 22038万美元 |
预测年份 [2024] | 26628万美元 |
预测年份 [2030] | 8.625 亿美元 |
复合年增长率(%) | 21.52% |
区域洞察
在包括美国和加拿大在内的美国地区,对早期检测和个人化医疗的重视正在推动基于人工智慧的癌症诊断的需求。着名的研究机构和公司正在大力投资人工智慧研究,FDA 等监管机构也急于核准人工智慧诊断工具。公司和学术机构提交的人工智慧专利申请反映了用于诊断成像和基因组资料分析的机器学习演算法的创新。一旦解决了对隐私和准确性的担忧,客户通常会接受人工智慧驱动的医疗保健服务。许多欧盟国家正在透过政府倡议在医疗保健领域进行全面的人工智慧研发活动。在该地区,由于人口老化和癌症发病率上升,客户对人工智慧在癌症诊断方面的需求很高。就顾客购买行为而言,欧洲倾向青睐符合严格 GDPR 法规的产品和服务。中东地区对智慧健康技术进行了大量投资,人工智慧癌症诊断工具的市场正在扩大。在亚太地区,随着人口老化推动消费者需求,癌症诊断领域的人工智慧市场正在扩大。在亚太地区,客户越来越精通技术,并对人工智慧医疗保健解决方案持开放态度,政府对人工智慧研究的支持正在为癌症诊断领域的人工智慧建立一个快速成长的市场。
FPNV定位矩阵
FPNV 定位矩阵对于评估供应商在癌症诊断市场人工智慧中的定位至关重要。此矩阵提供了对供应商的全面评估,并检验了与业务策略和产品满意度相关的关键指标。这种详细的评估使用户能够根据自己的要求做出明智的决定。根据评估,供应商被分为代表其成功程度的四个像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市场占有率分析
市场占有率分析是一个综合工具,可以对癌症诊断市场人工智慧供应商的现状进行深入而详细的评估。透过仔细比较和分析供应商的贡献,您可以更深入地了解每个供应商的绩效以及他们在争夺市场占有率时面临的挑战。这些贡献包括整体收益、客户群和其他重要指标。此外,该分析还提供了对该领域竞争性质的宝贵见解,包括累积研究期、片段化优势和合併特征等因素。有了这些详细信息,供应商可以做出更明智的决策并製定有效的策略,以在市场竞争中保持领先地位。
策略分析与建议
策略分析对于寻求在全球市场站稳脚跟的组织至关重要。对人工智慧在癌症诊断市场中的当前地位进行全面评估,使公司能够做出符合其长期愿望的明智决策。此关键评估涉及对组织的资源、能力和整体绩效进行彻底分析,以确定核心优势和需要改进的领域。
[193 Pages Report] The AI in Cancer Diagnostics Market size was estimated at USD 220.38 million in 2023 and expected to reach USD 266.28 million in 2024, at a CAGR 21.52% to reach USD 862.50 million by 2030.
Artificial Intelligence (AI) in cancer diagnostics involves the use of advanced algorithms and software to process, analyze, and interpret medical images and data for the detection, diagnosis, and prediction of cancer. These AI-driven systems are equipped with machine learning and deep learning capabilities, which enable them to learn from vast amounts of oncological data, improving their accuracy and efficiency over time. The increasing prevalence of cancer among the global population and the rising need for personalized medicine boost the adoption of AI in the healthcare sector. Moreover, proliferating adoption in several cancer screening programs worldwide, along with the exponential shift towards non-invasive cancer diagnosis, drives AI integration in cancer therapy. However, the high cost of AI-integrated cancer therapies and the shortage of trained oncologists impact the expansion of AI in the cancer diagnostics market. Furthermore, technological improvements in cancer diagnostics supported by government investments create lucrative opportunities for market growth.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 220.38 million |
Estimated Year [2024] | USD 266.28 million |
Forecast Year [2030] | USD 862.50 million |
CAGR (%) | 21.52% |
Regional Insights
In the American region, including the United States & Canada, the demand for AI-based cancer diagnostics is driven by a strong emphasis on early detection and personalized medicine. Prominent institutions and companies are investing heavily in AI research, and regulatory agencies such as the FDA are expediting approvals of AI diagnostic tools. Patent filings in AI from companies and academic institutions reflect the innovation in machine learning algorithms for imaging and genomic data analysis. Customers are generally receptive to AI-driven healthcare services, provided privacy and accuracy concerns are addressed. A host of EU countries engage in comprehensive AI research and development activities in the healthcare sector through government initiatives. The region shows a strong customer need for AI in cancer diagnostics due to aging populations and increased cancer prevalence. In terms of customer purchasing behavior, Europeans tend to favor products and services that comply with stringent GDPR regulations. In the Middle East, with substantial investments in smart health technologies, there's a growing market for AI cancer diagnostic tools. APAC region has a growing market for AI in cancer diagnostics, with its aging population driving consumer needs. In the APAC region, customers are increasingly tech-savvy and open to AI healthcare solutions, while the government's support of AI research has established a burgeoning market for AI in cancer diagnostics.
Market Insights
The market dynamics represent an ever-changing landscape of the AI in Cancer Diagnostics Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the AI in Cancer Diagnostics Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the AI in Cancer Diagnostics Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
Owkin Enters Collaboration Agreement With MSD to Develop AI-Powered Diagnostics for Cancer
Biotechnology firm Owkin has solidified a partnership with MSD, known as Merck & Co. in the United States, to pioneer AI-enhanced digital pathology diagnostics tailored for the European Union market. This groundbreaking collaboration aims to refine pre-screening methods for Microsatellite Instability-High (MSI-H), a genomic biomarker critical for prognosticating and guiding treatment in immunotherapy, specifically in cancers such as endometrial, gastric, small intestine, and biliary where MSI-H detection is currently not standard practice despite its significance. [Published On: 2023-12-19]
ConcertAI Announces Agreement with Cancer Center to Accelerate and Transform Precision Oncology Through AI-Enabled Imaging Solutions
ConcertAI has established a pivotal multi-year strategic partnership with Memorial Sloan Kettering Cancer Center (MSK) to focus on driving the advancement and implementation of clinical AI algorithms and enhancing imaging workflow integration within clinical trials, as well as augmenting oncology clinical decisions. MSK heralds these advancements as a catalyst for precise diagnostics and better management of treatment, fueling a transformative shift within the radiology and AI community that promises a leap in cancer diagnosis and patient care. [Published On: 2023-11-14]
Roche Collaborates with Ibex and Amazon Web Services to Accelerate Adoption of AI-Enabled Digital Pathology Solutions to Help Improve Cancer Diagnoses
F. Hoffmann-La Roche Ltd. has announced collaborations with Ibex Medical Analytics and Amazon Web Services to enhance cancer diagnostics through the navify digital pathology platform, which integrates cutting-edge AI tools for improved accuracy and efficiency in diagnosing breast and prostate cancer. These innovative collaborations aim to streamline pathology workflows by providing secure access to AI-driven decision support, enabling pathologists to deliver precise and expedited patient care. [Published On: 2023-10-26]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the AI in Cancer Diagnostics Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the AI in Cancer Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Aiosyn B.V., Cancer Center.ai, ContextVision AB, Deep Bio Inc., Google LLC by Alphabet Inc., Ibex Medical Analytics Ltd., International Business Machines Corporation, Kheiron Medical Technologies Limited, Lifebit Biotech Ltd, Lunit Inc., Medial EarlySign, Microsoft Corporation, Mindpeak GmbH, Paige AI, Inc., PathAI, Inc., Proscia Inc., Qritive, Quantib B.V., ScreenPoint Medical BV, Siemens Healthineers AG, Tempus Labs, Inc., Therapixel, Visiopharm A/S, Viz.ai, and Xavor Corporation.
Market Segmentation & Coverage